{"id":"adenosine-arm","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3896316","moleculeType":"Small molecule","molecularWeight":"654.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adenosine is an endogenous nucleoside that acts on adenosine receptors (A1, A2A, A2B, A3) to modulate immune responses and vascular function. An 'adenosine arm' in a clinical trial context may represent a treatment arm comparing adenosine-based therapy or adenosine receptor modulation against a control. The specific mechanism depends on which adenosine receptor is targeted and the therapeutic context.","oneSentence":"Adenosine arm likely refers to a therapeutic strategy leveraging adenosine signaling pathways, potentially for immunomodulation or cardioprotection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:59:43.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05377424","phase":"PHASE1, PHASE2","title":"Adenosine 2A Receptor Antagonism and AIH in ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-06-21","conditions":"ALS","enrollment":40},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT05149560","phase":"PHASE2","title":"Ticagrelor Monotherapy After Stenting","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2021-12-14","conditions":"Acute Myocardial Infarction","enrollment":200},{"nctId":"NCT05217498","phase":"PHASE1, PHASE2","title":"Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"Randy Trumbower, PT, PhD","startDate":"2027-09-01","conditions":"Spinal Cord Injuries, Myelopathy","enrollment":40},{"nctId":"NCT06463587","phase":"PHASE3","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-06-25","conditions":"Generalized Myasthenia Gravis","enrollment":264},{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":"Advanced Unresectable Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT06258525","phase":"PHASE2","title":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-03","conditions":"Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer","enrollment":30},{"nctId":"NCT06561360","phase":"PHASE2","title":"A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-09","conditions":"Hairy Cell Leukemia","enrollment":86},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06925646","phase":"","title":"Hand Perfusion and Pulse Oximetry Performance","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-09-01","conditions":"Oxygen Saturation","enrollment":20},{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT05494580","phase":"PHASE1, PHASE2","title":"Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-09-22","conditions":"Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":29},{"nctId":"NCT07456423","phase":"PHASE4","title":"Adenosine vs. Diltiazem","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2024-07-01","conditions":"Supraventricular Tachycardia (SVT), Atrioventricular Nodal Re Entrant Tachycardia","enrollment":140},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT04893109","phase":"PHASE2","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-16","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":500},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT06016387","phase":"PHASE2","title":"Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-11-25","conditions":"HER2-positive Breast Cancer, LMD","enrollment":30},{"nctId":"NCT04007055","phase":"PHASE3","title":"The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions","status":"TERMINATED","sponsor":"Marissa Jarosinski","startDate":"2019-08-09","conditions":"Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease","enrollment":31},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT05906914","phase":"PHASE2","title":"Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-26","conditions":"Acute Myeloid Leukemia, Adult","enrollment":65},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT07126561","phase":"PHASE2","title":"Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-11-01","conditions":"HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2","enrollment":43},{"nctId":"NCT03783351","phase":"NA","title":"Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2019-05-27","conditions":"Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents","enrollment":4009},{"nctId":"NCT05657652","phase":"NA","title":"CAV Regimen for R/R Ph- B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT05488431","phase":"PHASE2","title":"Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)","status":"RECRUITING","sponsor":"Priscilla Hsue, MD","startDate":"2023-03-01","conditions":"Dyslipidemias, Cardiovascular Diseases, HIV Infections","enrollment":121},{"nctId":"NCT07032727","phase":"PHASE2","title":"Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-12","conditions":"Targeted Therapy, IDH1-Mutated Malignancies, Mutations","enrollment":68},{"nctId":"NCT04240990","phase":"NA","title":"Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-11-04","conditions":"Tuberculosis, Severe Acute Malnutrition","enrollment":603},{"nctId":"NCT04457596","phase":"PHASE3","title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-03-02","conditions":"Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1056},{"nctId":"NCT05618925","phase":"PHASE1","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-08-22","conditions":"Non Hodgkin's Lymphoma Refractory/Relapsed","enrollment":20},{"nctId":"NCT05887271","phase":"PHASE2, PHASE3","title":"A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction","status":"RECRUITING","sponsor":"University of Leicester","startDate":"2023-12-05","conditions":"Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus, Type 2","enrollment":63},{"nctId":"NCT02250937","phase":"PHASE2","title":"Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":116},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT06893471","phase":"NA","title":"From Yearly Checks to Daily Progress: Evaluating Goal Attainment Scaling (GAS) in Systematic Work Environment Management (SAM) Within the Municipal Sector","status":"ENROLLING_BY_INVITATION","sponsor":"Karolinska Institutet","startDate":"2024-08-15","conditions":"Behavior Change Interventions, Work Environment Adverse Effects, Health Factors","enrollment":45},{"nctId":"NCT06591377","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-10","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT03869268","phase":"PHASE4","title":"The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2019-04-24","conditions":"Acute Coronary Syndrome","enrollment":72},{"nctId":"NCT04695080","phase":"PHASE2, PHASE3","title":"ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-06-25","conditions":"Advanced Multiple Sclerosis, Progressive Multiple Sclerosis","enrollment":204},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT04822649","phase":"NA","title":"Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2021-04-15","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF)","enrollment":100},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT04740918","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-07","conditions":"Metastatic Breast Cancer","enrollment":96},{"nctId":"NCT03218137","phase":"PHASE4","title":"Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-02-13","conditions":"Premature Ventricular Contraction (PVC)","enrollment":100},{"nctId":"NCT03326193","phase":"PHASE2","title":"A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-12-12","conditions":"Ovarian Neoplasms","enrollment":105},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT04042051","phase":"PHASE1","title":"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-11-12","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","enrollment":2},{"nctId":"NCT05650879","phase":"PHASE1","title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2023-03-20","conditions":"HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation","enrollment":198},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT03884556","phase":"PHASE1","title":"TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2019-04-10","conditions":"Solid Tumor, Lymphoma","enrollment":56},{"nctId":"NCT06578234","phase":"PHASE4","title":"Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses","status":"RECRUITING","sponsor":"Region Skane","startDate":"2024-10-23","conditions":"Chronic Coronary Syndrome, Coronary Artery Disease, Ischemic Heart Disease","enrollment":180},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT03682289","phase":"PHASE2","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2019-01-17","conditions":"Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm","enrollment":89},{"nctId":"NCT06644573","phase":"PHASE1","title":"Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Nyree Penn","startDate":"2025-11-01","conditions":"Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder","enrollment":100},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT05915442","phase":"PHASE2","title":"Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer","status":"RECRUITING","sponsor":"Catherine Spina","startDate":"2023-07-01","conditions":"Oligometastatic Prostate Cancer","enrollment":23},{"nctId":"NCT02733341","phase":"PHASE4","title":"The Effect of IV Cangrelor and Oral Ticagrelor Study","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2016-07-21","conditions":"Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO)","enrollment":100},{"nctId":"NCT03304717","phase":"PHASE1, PHASE2","title":"Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-12","conditions":"Aicardi Goutières Syndrome","enrollment":""},{"nctId":"NCT05201404","phase":"PHASE3","title":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","status":"RECRUITING","sponsor":"Can-Fite BioPharma","startDate":"2023-03-15","conditions":"Hepatocellular Carcinoma, Cirrhosis","enrollment":471},{"nctId":"NCT05766514","phase":"PHASE2","title":"Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2025-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT06554821","phase":"PHASE1","title":"A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-05","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT06112990","phase":"PHASE3","title":"Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-11-09","conditions":"Metastatic Prostate Cancer","enrollment":200},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT06586320","phase":"NA","title":"Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"Stardots AB","startDate":"2025-02-06","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT03329937","phase":"PHASE1","title":"Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2018-04-12","conditions":"Neoplasms, Breast","enrollment":21},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT06119217","phase":"PHASE2","title":"Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trishula Therapeutics, Inc.","startDate":"2024-03-25","conditions":"Pancreatic Cancer","enrollment":194},{"nctId":"NCT03726879","phase":"PHASE3","title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-11","conditions":"Breast Cancer","enrollment":454},{"nctId":"NCT06667349","phase":"PHASE4","title":"TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2023-08-24","conditions":"STEMI - ST Elevation Myocardial Infarction, Stent Thrombosis, Antiplatelet Agents","enrollment":1727},{"nctId":"NCT02390427","phase":"PHASE1","title":"Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Otto Metzger, MD","startDate":"2015-04-20","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":68},{"nctId":"NCT05986968","phase":"NA","title":"Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2023-07-06","conditions":"ST Elevation Myocardial Infarction","enrollment":200},{"nctId":"NCT06591390","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-02-09","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06591312","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT02096055","phase":"PHASE2","title":"Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-04-04","conditions":"Untreated Adult Acute Myeloid Leukemia","enrollment":44},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT06561867","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-30","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06196047","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2023-12-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06202755","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-03-30","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT03530696","phase":"PHASE2","title":"T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2018-12-06","conditions":"HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage","enrollment":55},{"nctId":"NCT04521569","phase":"EARLY_PHASE1","title":"Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-22","conditions":"Lung Transplant","enrollment":47},{"nctId":"NCT06281067","phase":"NA","title":"Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine","status":"RECRUITING","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2023-12-15","conditions":"Myocardial Bridge","enrollment":500},{"nctId":"NCT02016170","phase":"NA","title":"Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-03","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":82},{"nctId":"NCT01566890","phase":"NA","title":"Microvascular Blood Flow in Sickle Cell Anemia","status":"COMPLETED","sponsor":"Versiti Blood Health","startDate":"2012-07","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":91},{"nctId":"NCT04336098","phase":"PHASE1","title":"Study of SRF617 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-03-16","conditions":"Advanced Solid Tumor","enrollment":85},{"nctId":"NCT05553613","phase":"PHASE3","title":"Ticagrelor Versus Clopidogrel in Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-10-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT03119012","phase":"PHASE4","title":"P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2017-04-19","conditions":"Coronary Artery Disease, Stents, Atherosclerosis","enrollment":25},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT02715518","phase":"NA","title":"FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2016-08-19","conditions":"Acute Myocardial Infarction","enrollment":1292},{"nctId":"NCT06125834","phase":"PHASE2","title":"Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-01","conditions":"Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine","enrollment":36},{"nctId":"NCT06363006","phase":"PHASE1","title":"Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-03-11","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT01120184","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07-31","conditions":"Breast Cancer","enrollment":1095},{"nctId":"NCT02862119","phase":"NA","title":"Ffr-gUidance for compLete Non-cuLprit REVASCularization","status":"COMPLETED","sponsor":"Felix Bohm","startDate":"2016-08-08","conditions":"Coronary Artery Disease, ST-elevation Myocardial Infarction","enrollment":1542},{"nctId":"NCT02150902","phase":"NA","title":"Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence","status":"UNKNOWN","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2015-03","conditions":"Atrial Fibrillation","enrollment":411},{"nctId":"NCT05573373","phase":"PHASE1","title":"Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2022-12-20","conditions":"Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1249,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["APPLE"],"phase":"phase_3","status":"active","brandName":"Adenosine arm","genericName":"Adenosine arm","companyName":"Yong Seog Oh","companyId":"yong-seog-oh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}